Effectiveness of molnupiravir for the treatment of COVID-19: a systematic literature review of real-world observational studies.

IF 2.2 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Samantha G Bromfield, Ramu Periyasamy, Veeri Rajendra Babu, Amy Puenpatom, Deanna D Hill
{"title":"Effectiveness of molnupiravir for the treatment of COVID-19: a systematic literature review of real-world observational studies.","authors":"Samantha G Bromfield, Ramu Periyasamy, Veeri Rajendra Babu, Amy Puenpatom, Deanna D Hill","doi":"10.1080/03007995.2025.2551227","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Molnupiravir (MOV), an oral antiviral, is prescribed to treat adult patients with mild-to-moderate COVID-19 at risk of progressing to severe disease. Previous systematic literature reviews (SLRs) have evaluated the effectiveness of MOV in the general population; however, evidence on high-risk population is lacking. This SLR assessed the real-world effectiveness of MOV for reducing the progression to severe COVID-19 outcomes in clinical settings, including high-risk or special populations (such as patients with type 2 diabetes, chronic respiratory diseases, immunocompromised conditions, older adults, and nursing home residents) who have limited alternative COVID-19 treatment options.</p><p><strong>Methods: </strong>We searched EMBASE and PubMed databases for studies published between 1 January 2021 and 24 May 2024, using predefined search terms related to MOV. Studies comparing MOV-treated with untreated groups of non-hospitalized adults at risk of progression to severe COVID-19 outcomes (hospitalization, death, and the composite of hospitalization/death) were included. Risk of bias of the included studies was assessed using the ROBINS-I tool.</p><p><strong>Results: </strong>Twenty-one general and special population studies were included. General population studies (<i>n</i> = 16) showed that MOV reduced the risk of death, hospitalization, and hospitalization/death. Special population studies (<i>n</i> = 10; five additional and five general population articles with subgroups of interest) also showed that MOV reduced the risk of the same outcomes, with a more pronounced effect in older adults (≥60 years). The wide range of risk reduction observed might be attributed to variability in COVID-19 hospitalization guidelines and vaccination status.</p><p><strong>Conclusions: </strong>Findings from this SLR suggest that MOV may reduce the risk of hospitalization, death, and hospitalization/death compared with untreated groups, including high-risk adults with underlying comorbidities. Further studies are needed to confirm the effectiveness of MOV in high-risk or special populations.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-22"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2551227","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Molnupiravir (MOV), an oral antiviral, is prescribed to treat adult patients with mild-to-moderate COVID-19 at risk of progressing to severe disease. Previous systematic literature reviews (SLRs) have evaluated the effectiveness of MOV in the general population; however, evidence on high-risk population is lacking. This SLR assessed the real-world effectiveness of MOV for reducing the progression to severe COVID-19 outcomes in clinical settings, including high-risk or special populations (such as patients with type 2 diabetes, chronic respiratory diseases, immunocompromised conditions, older adults, and nursing home residents) who have limited alternative COVID-19 treatment options.

Methods: We searched EMBASE and PubMed databases for studies published between 1 January 2021 and 24 May 2024, using predefined search terms related to MOV. Studies comparing MOV-treated with untreated groups of non-hospitalized adults at risk of progression to severe COVID-19 outcomes (hospitalization, death, and the composite of hospitalization/death) were included. Risk of bias of the included studies was assessed using the ROBINS-I tool.

Results: Twenty-one general and special population studies were included. General population studies (n = 16) showed that MOV reduced the risk of death, hospitalization, and hospitalization/death. Special population studies (n = 10; five additional and five general population articles with subgroups of interest) also showed that MOV reduced the risk of the same outcomes, with a more pronounced effect in older adults (≥60 years). The wide range of risk reduction observed might be attributed to variability in COVID-19 hospitalization guidelines and vaccination status.

Conclusions: Findings from this SLR suggest that MOV may reduce the risk of hospitalization, death, and hospitalization/death compared with untreated groups, including high-risk adults with underlying comorbidities. Further studies are needed to confirm the effectiveness of MOV in high-risk or special populations.

莫努匹拉韦治疗COVID-19的有效性:对现实世界观察性研究的系统文献综述
目的:口服抗病毒药物莫努皮拉韦(Molnupiravir, MOV)用于治疗有进展为严重疾病风险的轻中度成人COVID-19患者。以前的系统文献综述(slr)已经评估了MOV在普通人群中的有效性;然而,缺乏关于高危人群的证据。该SLR评估了MOV在临床环境中减少COVID-19严重结局进展的实际有效性,包括高风险或特殊人群(如2型糖尿病患者、慢性呼吸道疾病患者、免疫功能低下患者、老年人和养老院居民),他们的COVID-19替代治疗方案有限。方法:我们在EMBASE和PubMed数据库中检索了2021年1月1日至2024年5月24日期间发表的研究,使用与MOV相关的预定义搜索词。纳入了比较movo治疗组和未治疗组的非住院成人进展为严重COVID-19结局(住院、死亡和住院/死亡复合)风险的研究。使用ROBINS-I工具评估纳入研究的偏倚风险。结果:纳入了21项一般和特殊人群研究。一般人群研究(n = 16)显示,MOV降低了死亡、住院和住院/死亡风险。特殊人群研究(n = 10,另外5篇和5篇一般人群研究的亚组研究)也显示MOV降低了相同结局的风险,在老年人(≥60岁)中效果更明显。观察到的大范围风险降低可能归因于COVID-19住院指南和疫苗接种状况的差异。结论:该单反研究结果表明,与未治疗组相比,MOV可降低住院、死亡和住院/死亡风险,包括伴有潜在合并症的高危成人。需要进一步的研究来证实MOV在高危人群或特殊人群中的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Medical Research and Opinion
Current Medical Research and Opinion 医学-医学:内科
CiteScore
4.40
自引率
4.30%
发文量
247
审稿时长
3-8 weeks
期刊介绍: Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信